CRISPR Genome Editing Market Size and Segment Forecasts, 2019 - 2028

WILMINGTON, Del. - July 14, 2022 - PRLog -- CRISPR Genome Editing Market Segmental Overview

The CRISPR genome editing market is classified into by applications, end-user, and geography

CRISPR Genome Editing Devices Market Developments

December 2018: Intellia Therapeutics, Inc., a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced an expansion of its existing cell therapy collaboration with Novartis, to include the ex vivo development of innovative cell therapies using certain ocular stem cells.

August 28, 2018: Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, announced that is has entered into a collaboration with a global pharma partner to co-develop and apply a novel cutting-edge research tool for target identification and validation.

January 2015: Novartis announced that it has signed collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology and Caribou Biosciences for the development of drug discovery tools.

Get Free Sample Report for More Industry Insights: https://www.axiommrc.com/request-for-sample/hc2019-crispr-genome-editing-market-report